The opioid giant Mallinckrodt, a major player in the US pharmaceutical market, was forced to release over 1.3 million internal documents revealing deceptive marketing practices and efforts to shape medical opinions. The company, known for selling a significant amount of prescription opioids, employed tactics like developing educational programs, influencing key opinion leaders, and promoting the concept of “pseudoaddiction” to increase sales. Despite legal battles and bankruptcy filings, Mallinckrodt continues to sell opioids. The documents shed light on how drug companies manipulate medical science and opinion for profit, highlighting the need for greater transparency and oversight in the pharmaceutical industry.
Source link
How an opioid giant deployed a playbook for moulding doctors’ minds
